2型糖尿病性骨质疏松降糖药物的选择  

Selection of hypoglycemic drugs in the treatment of osteoporosis with type 2 diabetis

作　　者：李嘉萍[1] 齐明宇 宋永波[1] 田雷[1] 王立芳[1] 

机构地区：[1]吉林省吉林市中心医院内分泌科,吉林132011

出　　处：《中国骨质疏松杂志》2014年第8期985-987,共3页Chinese Journal of Osteoporosis

摘　　要：近年来,随着对糖尿病性骨质疏松研究的深入,2型糖尿病性骨质疏松降糖药物的选择也越来越引起人们的重视。肠促胰素、二甲双胍、胰岛素促泌剂等在抑制骨吸收、促进骨合成及诱导骨髓间充质细胞分化等多个层面上对2型糖尿病性骨质疏松可能有正面影响。胰岛素对骨质疏松的影响虽然有争议,但早期持续胰岛素治疗对糖尿病性骨质疏松的发生和发展可能具有控制和延缓作用,噻唑烷二酮类药物可显著增加2型糖尿病女性患者骨折发生率。In the recent years,along with the in-depth study of diabetic osteoporosis,more and more attention has been paid to the medication choices in the treatment of type 2 diabetic osteoporosis. Incretin,metformin,and insulin secretagogues can inhibit bone resorption,promote bone synthesis,and induce the differentiation of bone marrow mesenchymal cells in many aspects,which may have positive effect on the type 2 diabetic osteoporosis. The effect of insulin on osteoporosis is still controversial,but the continuous insulin therapy at the early stage could control and delay the occurrence and development of diabetic osteoporosis. The thiazolidinediones can significantly increase the incidence of fractures in women with type 2 diabetes mellitus.

关 键 词：2型糖尿病 骨质疏松 降糖药物 

分 类 号：R979.9[医药卫生—药品]